-The Telegraph New Delhi: A government agency has blocked its own pledge to impose price control on more medicines by withdrawing guidelines that it had used in July this year to cap prices of drugs used to treat diabetes and cardiovascular diseases. The National Pharmaceutical Pricing Authority (NPPA) has withdrawn the guidelines issued under Paragraph 19 of the Drug Price Control Order that it had used in July this year to cap...
More »SEARCH RESULT
Total Matching Records found : 121
Government curbs power of regulator to cap HIV, cancer drug prices -Rupali Mukherjee
-The Times of India MUMBAI: In a move that will disappoint many patients, the government has withdrawn certain powers of the drug pricing regulator that allowed it to cap prices of widely prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines. The National Pharmaceutical Pricing Authority (NPPA) said it is withdrawing "with immediate effect" - a guideline that had allowed it to put price caps on crucial medicines - to comply with a...
More »A new order
-The Business Standard A ray of hope for Indian generic drug makers Gilead Sciences, the California-headquartered biotechnology company, has authorised seven India-based drug makers - Cipla, Ranbaxy, Mylan, Strides Arcolab, Hetero, Cadila Healthcare and Sequent Scientific - to manufacture and sell the generic versions of its hepatitis C medicine, Sovaldi, in 91 developing countries. Earlier in the week, Lupin, the fourth largest Indian drug maker, announced that it will develop and supply...
More »Major diabetes, cardiac drugs to become up to 35% cheaper -Rupali Mukherjee
-The Times of India MUMBAI: In a move that has surprised and shaken the industry, prices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35% over the next few weeks, with the drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA), deciding to bring them under price control. In a rare invocation of a lesser-used provision in the Drug Price Control Order (DPCO), NPPA has fixed the prices...
More »Drug price control covers too little, riddled with loopholes -GS Mudur
-The Telegraph New Delhi: The price caps imposed by the Indian government on 348 drugs earlier this year have created only an illusion of control, keeping many medicines for conditions ranging from asthma to diabetes and heart disease beyond price regulations, experts said today. The price control order issued by the department of pharmaceuticals in May has led to a 22 per cent reduction in the average cost of some 250 medicines,...
More »
